Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Clouds Darken Over Gilead's Zydelig In Europe Amid EMA Review

This article was originally published in Scrip

Executive Summary

A fresh obstacle to Gilead Sciences Inc.'s blood cancer therapy Zydelig (idelalisib) is looming amid news the European Medicines Agency is reviewing the PI3K inhibitor's safety profile after a jump in serious adverse events, including deaths, mostly due to infections, observed in three clinical studies.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register